News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
698,558 Results
Type
Article (39678)
Company Profile (247)
Press Release (658633)
Multimedia
Podcasts (49)
Webinars (12)
Section
Business (204159)
Career Advice (2007)
Deals (35416)
Drug Delivery (95)
Drug Development (81042)
Employer Resources (172)
FDA (16178)
Job Trends (14856)
News (345170)
Policy (32535)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (7)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (17)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (5)
2024 Genetown Standard (8)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (4)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (5)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Standard (2)
Academia (2554)
Accelerated approval (5)
Adcomms (20)
Allergies (84)
Alliances (49426)
ALS (88)
Alzheimer's disease (1376)
Antibody-drug conjugate (ADC) (124)
Approvals (16184)
Artificial intelligence (249)
Autoimmune disease (21)
Automation (16)
Bankruptcy (360)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (105)
Biotechnology (175)
Bladder cancer (77)
Brain cancer (27)
Breast cancer (278)
Cancer (2245)
Cardiovascular disease (173)
Career advice (1675)
Career pathing (30)
CAR-T (149)
Cell therapy (418)
Cervical cancer (19)
Clinical research (65966)
Collaboration (832)
Compensation (524)
Complete response letters (19)
COVID-19 (2588)
CRISPR (39)
C-suite (238)
Cystic fibrosis (100)
Data (2186)
Decentralized trials (2)
Denatured (18)
Depression (41)
Diabetes (268)
Diagnostics (6365)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (120)
Drug pricing (98)
Drug shortages (25)
Duchenne muscular dystrophy (93)
Earnings (86554)
Editorial (36)
Employer branding (21)
Employer resources (146)
Events (112319)
Executive appointments (717)
FDA (17417)
Featured Employer (47)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (746)
Gene editing (103)
Generative AI (19)
Gene therapy (299)
GLP-1 (704)
Government (4414)
Grass and pollen (4)
Guidances (55)
Healthcare (18814)
Huntington's disease (23)
IgA nephropathy (27)
Immunology and inflammation (114)
Indications (29)
Infectious disease (2730)
Inflammatory bowel disease (136)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (96)
Interviews (311)
IPO (16507)
IRA (40)
Job creations (3630)
Job search strategy (1422)
Kidney cancer (10)
Labor market (38)
Layoffs (465)
Leadership (16)
Legal (7909)
Liver cancer (75)
Lung cancer (320)
Lymphoma (152)
Machine learning (7)
Management (58)
Manufacturing (302)
MASH (66)
Medical device (13372)
Medtech (13377)
Mergers & acquisitions (19451)
Metabolic disorders (678)
Multiple sclerosis (79)
NASH (16)
Neurodegenerative disease (88)
Neuropsychiatric disorders (27)
Neuroscience (1906)
NextGen: Class of 2025 (6512)
Non-profit (4480)
Northern California (2661)
Now hiring (39)
Obesity (361)
Opinion (204)
Ovarian cancer (75)
Pain (83)
Pancreatic cancer (83)
Parkinson's disease (148)
Partnered (21)
Patents (231)
Patient recruitment (108)
Peanut (46)
People (57284)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20547)
Phase II (29048)
Phase III (21644)
Pipeline (1178)
Policy (137)
Postmarket research (2563)
Preclinical (8733)
Press Release (64)
Prostate cancer (106)
Psychedelics (30)
Radiopharmaceuticals (246)
Rare diseases (378)
Real estate (5907)
Recruiting (65)
Regulatory (22266)
Reports (46)
Research institute (2320)
Resumes & cover letters (349)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (68)
Series A (129)
Series B (84)
Service/supplier (11)
Sickle cell disease (52)
Southern California (2282)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3575)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (37)
The Weekly (29)
United States (22909)
Vaccines (684)
Venture capitalists (41)
Weight loss (231)
Women's health (35)
Worklife (15)
Date
Today (221)
Last 7 days (877)
Last 30 days (2704)
Last 365 days (32876)
2025 (10456)
2024 (35218)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (718)
Alabama (53)
Alaska (7)
Arizona (231)
Arkansas (13)
Asia (37830)
Australia (6184)
California (6070)
Canada (2004)
China (518)
Colorado (265)
Connecticut (272)
Delaware (146)
Europe (81212)
Florida (901)
Georgia (204)
Idaho (57)
Illinois (528)
India (25)
Indiana (306)
Iowa (11)
Japan (159)
Kansas (104)
Kentucky (23)
Louisiana (10)
Maine (62)
Maryland (885)
Massachusetts (4527)
Michigan (216)
Minnesota (388)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (63)
New Hampshire (63)
New Jersey (1711)
New Mexico (28)
New York (1727)
North Carolina (960)
North Dakota (8)
Northern California (2661)
Ohio (202)
Oklahoma (14)
Oregon (34)
Pennsylvania (1366)
Puerto Rico (12)
Rhode Island (33)
South America (1096)
South Carolina (22)
South Dakota (1)
Southern California (2282)
Tennessee (101)
Texas (898)
Utah (180)
Virginia (143)
Washington D.C. (61)
Washington State (549)
West Virginia (3)
Wisconsin (53)
698,558 Results for "gradalis inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Gradalis Announces Development of Clinically Relevant Exome Sequencing Bioinformatics Pipeline to Determine Clonal Tumor Mutation Burden
March 17, 2025
·
8 min read
Press Releases
Gradalis Secures FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Vigil® (Gemogenovatucel-T): An Investigational Personalized Immunotherapy for Advanced Ovarian Cancer
February 5, 2025
·
6 min read
Lone Star Bio
Gradalis Awarded $9.9 Million Grant From the Cancer Prevention and Research Institute of Texas
Gradalis, Inc. announced that it has been awarded a $9.9 million Product Development Research grant from the Cancer Prevention and Research Institute of Texas.
November 16, 2023
·
9 min read
Lone Star Bio
Gradalis to Participate in the Cantor Global Healthcare Conference
Gradalis, Inc. today announced that Steven Engle, Chief Executive Officer, will participate in a fireside chat and one-on-one meetings at the Cantor Global Healthcare Conference, being held in New York, NY from September 26-28, 2023.
September 21, 2023
·
4 min read
Lone Star Bio
Gradalis Highlights Importance of Targeting Clonal Neoantigens in Achieving Durable Benefit in Cancer Treatment
Gradalis, Inc. announced a peer-reviewed publication in Cancers, highlighting the newly discovered critical clinical role of clonal neoantigens in the durable efficacy of immunotherapies in oncology and the potential to use clonal neoantigens as a new biomarker to better identify patients who will best respond to certain immunotherapies.
December 5, 2023
·
12 min read
Lone Star Bio
Gradalis’ GRAD1405 bi-shRNAi Candidate First to Show Positive Impact on Three Key KRAS Mutations Identified in Drug Resistant Lung, Colon and Pancreatic Cancers
Gradalis, Inc., a clinical-stage biotechnology company developing personalized anti-cancer therapies, announced GRAD1405 has demonstrated robust, dose-related tumor growth control.
January 4, 2024
·
7 min read
Lone Star Bio
Gradalis Highlights Importance of Clonal Neoantigen Targeting for Clinical Benefit of Vigil® in Oncology Reviews Publication
Gradalis, Inc. announced the peer-reviewed publication in Oncology Reviews, a Frontiers Open Access Journal, highlighting Vigil activity in ovarian cancer related to clonal neoantigen expression and the HRP molecular profile.
September 28, 2023
·
7 min read
Lone Star Bio
Gradalis to Host Virtual KOL Discussion on the Vigil® Platform Entering Phase 2 for Platinum-Sensitive Recurrent Ovarian Cancer on October 25, 2023
Gradalis, Inc. announced that it will host a virtual KOL discussion on the Vigil® platform entering Phase 2 for platinum-sensitive recurrent ovarian cancer on Wednesday, October 25, 2023 at 11:00am ET.
October 18, 2023
·
7 min read
Business
Solve GNE and Gradalis Sign Agreement to Develop a Novel Gene Therapy Targeting HIBM
Solve GNE announced today that it has entered into a sponsored research agreement with Gradalis, Inc. to provide funding for a novel lipid nanoparticle gene therapy aimed at curing GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM).
July 31, 2023
·
5 min read
Lone Star Bio
Gradalis to Participate in the Cantor Fitzgerald Future of Oncology Symposium
Gradalis, Inc. today announced that Steven Engle, Chief Executive Officer, will participate in a fireside chat at the Cantor Fitzgerald Future of Oncology Symposium, being held virtually from April 3 – 5, 2023.
March 29, 2023
·
3 min read
1 of 69,856
Next
